Viatris Inc. (VTRS) Investor Relations Documents

Viatris Inc. (VTRS) investor relations documents from the company's IR site: 10 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-06	Press release	Viatris Reports Second-Quarter 2026 Financial Results
2026-08-04	Press release	Viatris Announces Quarterly Dividend
2026-07-29	Press release	Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
2026-07-01	Press release	Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026
2026-06-29	Press release	Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin
2026-05-18	Press release	U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pa
2026-05-07	Press release	Viatris Reports First-Quarter 2026 Financial Results
2026-05-07	Press release	Viatris to Present at the Bank of America Securities 2026 Healthcare Conference
2026-05-05	Press release	Viatris Announces Quarterly Dividend
2026-05-04	Press release	Viatris Announces Chief Financial Officer Transition

VTRS overview · VTRS earnings · VTRS financials · VTRS KPIs · VTRS documents · VTRS ownership · VTRS peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.